1	The	the	DT	_	3	det	_
2	European	european	NNP	_	3	nn	_
3	Commission	commission	NNP	_	8	nsubj	8:A0=PAG
4	(	(	-LRB-	_	3	punct	_
5	EC	ec	NNP	_	3	appos	_
6	)	)	-RRB-	_	3	punct	_
7	has	have	VBZ	_	8	aux	_
8	granted	grant	VBN	pb=grant.01	0	root	_
9	marketing	marketing	NN	p2=VBG	10	nn	_
10	authorisation	authorisation	NN	_	8	dobj	8:A1
11	to	to	IN	p2=TO	8	prep	8:A2
12	Janssen	janssen	NNP	_	14	hmod	_
13	-	-	HYPH	p2=:	14	hyph	_
14	Cilag	cilag	NNP	_	15	nn	_
15	International	international	NNP	_	20	poss	_
16	's	's	POS	_	15	possessive	_
17	next	next	JJ	_	18	amod	_
18	generation	generation	NN	_	20	nn	_
19	protease	protease	NN	p2=VBP	20	nn	_
20	inhibitor	inhibitor	NN	p2=CC	11	pobj	_
21	(	(	-LRB-	_	20	punct	_
22	PI	pi	NNP	p2=NN	20	appos	_
23	)	)	-RRB-	_	26	punct	_
24	Olysio	olysio	NNP	_	26	nn	_
25	(	(	-LRB-	_	26	punct	_
26	simeprevir	simeprevir	NNP	p2=NN	20	appos	_
27	)	)	-RRB-	_	26	punct	_
28	for	for	IN	_	8	prep	_
29	the	the	DT	_	30	det	_
30	treatment	treatment	NN	_	28	pobj	_
31	of	of	IN	_	30	prep	_
32	adults	adult	NNS	_	31	pobj	_
33	with	with	IN	_	32	prep	_
34	genotype	genotype	NN	p2=NNS	33	pobj	_
35	1	0	CD	_	34	num	_
36	and	and	CC	_	34	cc	_
37	4	0	CD	_	40	num	_
38	chronic	chronic	JJ	_	40	amod	_
39	hepatitis	hepatitis	NN	_	40	nn	_
40	C	c	NN	p2=NNP	34	conj	_
41	(	(	-LRB-	_	40	punct	_
42	CHC	chc	NNP	_	40	appos	_
43	)	)	-RRB-	_	40	punct	_
44	,	,	,	_	40	punct	_
45	in	in	IN	_	40	prep	_
46	combination	combination	NN	_	45	pobj	_
47	with	with	IN	_	46	prep	_
48	other	other	JJ	_	50	amod	_
49	medicinal	medicinal	JJ	_	50	amod	_
50	products	product	NNS	_	47	pobj	_
51	.	.	.	_	8	punct	_

1	This	this	DT	_	3	det	_
2	marketing	marketing	NN	p2=VBG	3	nn	_
3	authorisation	authorisation	NN	_	4	nsubj	4:A0=PAG
4	represents	represent	VBZ	pb=represent.01	0	root	_
5	a	a	DT	_	7	det	_
6	significant	significant	JJ	_	7	amod	_
7	milestone	milestone	NN	_	4	dobj	4:A1=PPT
8	in	in	IN	_	7	prep	_
9	the	the	DT	_	10	det	_
10	development	development	NN	_	8	pobj	_
11	of	of	IN	_	10	prep	_
12	new	new	JJ	_	16	amod	_
13	triple	triple	JJ	_	14	amod	_
14	therapy	therapy	NN	_	16	nn	_
15	hepatitis	hepatitis	NN	_	16	nn	_
16	C	c	NN	p2=NNP	21	nn	_
17	(	(	-LRB-	_	16	punct	_
18	HCV	hcv	NNP	p2=NN	16	appos	_
19	)	)	-RRB-	_	16	punct	_
20	treatment	treatment	NN	_	21	nn	_
21	options	option	NNS	_	11	pobj	_
22	for	for	IN	_	21	prep	_
23	genotype	genotype	NN	p2=NNS	22	pobj	_
24	1	0	CD	_	23	num	_
25	and	and	CC	_	23	cc	_
26	4	0	CD	_	27	num	_
27	patients	patient	NNS	_	23	conj	_
28	.	.	.	_	4	punct	_

1	It	it	PRP	_	3	nsubj	3:A2=GOL
2	also	also	RB	_	3	advmod	3:AM-DIS
3	includes	include	VBZ	pb=include.01	0	root	_
4	simeprevir	simeprevir	NN	p2=JJ	3	dobj	3:A1=PPT
5	as	as	IN	_	3	prep	_
6	part	part	NN	_	5	pobj	_
7	of	of	IN	_	6	prep	_
8	an	an	DT	_	24	det	_
9	all	all	DT	p2=PDT	10	advmod	_
10	oral	oral	JJ	_	24	amod	_
11	12	0	CD	_	13	hmod	_
12	-	-	HYPH	_	13	hyph	_
13	week	week	NN	_	16	npadvmod	_
14	IFN	ifn	NN	p2=NNP	16	hmod	_
15	-	-	HYPH	_	16	hyph	_
16	free	free	JJ	_	20	amod	_
17	direct	direct	RB	p2=JJ	19	hmod	_
18	-	-	HYPH	_	19	hyph	_
19	acting	act	VBG	_	20	amod	_
20	antiviral	antiviral	JJ	_	24	nsubj	_
21	(	(	-LRB-	_	20	punct	_
22	DAA	daa	NNP	p2=NN	20	appos	_
23	)	)	-RRB-	_	20	punct	_
24	regimen	regimen	VBP	p2=VB	7	pobj	_
25	with	with	IN	_	24	prep	_
26	or	or	CC	_	25	cc	_
27	without	without	IN	_	25	conj	_
28	RBV	rbv	NNP	_	27	pobj	_
29	,	,	,	_	27	punct	_
30	in	in	IN	_	24	prep	_
31	genotype	genotype	NN	p2=JJ	30	pobj	_
32	1	0	CD	_	35	nn	_
33	or	or	CC	_	32	cc	_
34	4	0	CD	_	32	conj	_
35	patients	patient	NNS	_	25	pobj	38:A1=PPT
36	,	,	,	_	35	punct	_
37	who	who	WP	_	38	nsubj	38:R-A1
38	are	be	VBP	pb=be.01	35	rcmod	_
39	intolerant	intolerant	JJ	_	38	acomp	38:A2=PRD
40	to	to	IN	p2=TO	39	prep	_
41	or	or	CC	_	39	cc	_
42	ineligible	ineligible	JJ	p2=VB	39	conj	_
43	for	for	IN	_	42	prep	_
44	IFN	ifn	NNP	p2=JJ	45	nn	_
45	treatment	treatment	NN	_	43	pobj	_
46	.	.	.	_	3	punct	_

1	"	"	``	_	8	punct	_
2	The	the	DT	_	5	det	_
3	EC	ec	NNP	_	4	nn	_
4	marketing	marketing	NN	_	5	nn	_
5	authorisation	authorisation	NN	_	8	nsubj	8:A1=PPT
6	for	for	IN	_	5	prep	_
7	simeprevir	simeprevir	NN	p2=NNP	6	pobj	_
8	is	be	VBZ	pb=be.01	0	root	_
9	a	a	DT	_	11	det	_
10	great	great	JJ	_	11	amod	_
11	milestone	milestone	NN	_	8	attr	8:A2=PRD
12	as	as	IN	_	14	mark	_
13	it	it	PRP	_	14	nsubj	14:A0=PAG
14	adds	add	VBZ	pb=add.02	8	advcl	8:AM-ADV
15	an	an	DT	_	19	det	_
16	important	important	JJ	_	19	amod	_
17	new	new	JJ	_	19	amod	_
18	treatment	treatment	NN	_	19	nn	_
19	option	option	NN	_	14	dobj	14:A1=PPT
20	for	for	IN	_	19	prep	_
21	patients	patient	NNS	_	20	pobj	_
22	,	,	,	_	14	punct	_
23	demonstrating	demonstrate	VBG	pb=demonstrate.01	14	advcl	_
24	the	the	DT	_	26	det	_
25	continued	continued	JJ	p2=VBN	26	amod	_
26	role	role	NN	_	23	dobj	23:A1=PPT
27	of	of	IN	_	26	prep	_
28	triple	triple	JJ	_	29	nn	_
29	therapy	therapy	NN	_	27	pobj	_
30	in	in	IN	_	26	prep	_
31	the	the	DT	_	32	det	_
32	treatment	treatment	NN	_	30	pobj	_
33	of	of	IN	_	32	prep	_
34	HCV	hcv	NNP	p2=NN	33	pobj	_
35	.	.	.	_	8	punct	_

1	In	in	IN	_	19	prep	19:AM-DIS
2	addition	addition	NN	_	1	pobj	_
3	,	,	,	_	19	punct	_
4	the	the	DT	_	5	det	_
5	introduction	introduction	NN	_	19	nsubj	19:A0=PAG
6	of	of	IN	_	5	prep	_
7	an	an	DT	_	18	det	_
8	all	all	DT	p2=RB	9	advmod	_
9	oral	oral	JJ	_	18	amod	_
10	,	,	,	_	18	punct	_
11	12	0	CD	_	13	hmod	_
12	-	-	HYPH	_	13	hyph	_
13	week	week	NN	_	19	nn	_
14	interferon	interferon	NN	_	16	hmod	_
15	-	-	HYPH	_	16	hyph	_
16	free	free	JJ	_	17	amod	_
17	treatment	treatment	NN	_	18	nn	_
18	regimen	regimen	NN	p2=NNS	6	pobj	_
19	provides	provide	VBZ	pb=provide.01	46	ccomp	46:A1=PPT
20	a	a	DT	_	22	det	_
21	new	new	JJ	_	22	amod	_
22	option	option	NN	_	19	dobj	19:A1=PPT
23	for	for	IN	_	22	prep	_
24	sustained	sustained	JJ	p2=VBN	26	amod	_
25	virologic	virologic	JJ	p2=NN	26	amod	_
26	response	response	NN	_	23	pobj	_
27	in	in	IN	_	26	prep	_
28	HCV	hcv	NNP	p2=NN	29	nn	_
29	patients	patient	NNS	_	27	pobj	_
30	with	with	IN	_	26	prep	_
31	genotypes	genotype	NNS	_	30	pobj	_
32	1	0	CD	_	35	nn	_
33	or	or	CC	_	32	cc	_
34	4	0	CD	_	32	conj	_
35	intolerant	intolerant	NN	p2=JJ	48	nn	_
36	to	to	IN	p2=TO	31	prep	_
37	or	or	CC	_	9	cc	_
38	ineligible	ineligible	JJ	p2=VB	36	pobj	_
39	for	for	IN	_	38	prep	_
40	interferon	interferon	NN	_	42	hmod	_
41	-	-	HYPH	_	42	hyph	_
42	based	base	VBN	_	43	amod	_
43	treatment	treatment	NN	_	39	pobj	_
44	,	,	,	_	46	punct	_
45	"	"	''	_	46	punct	_
46	said	say	VBD	pb=say.01	0	root	_
47	Thomas	thomas	NNP	_	48	nn	_
48	Stark	stark	NNP	_	46	nsubj	46:A0
49	,	,	,	_	48	punct	_
50	medical	medical	JJ	_	51	amod	_
51	director	director	NN	_	48	appos	_
52	,	,	,	_	48	punct	_
53	Janssen	janssen	NNP	_	54	nn	_
54	EMEA	emea	NNP	_	48	appos	_
55	.	.	.	_	46	punct	_

1	HCV	hcv	NNP	p2=NN	2	nsubj	2:A0=PAG
2	represents	represent	VBZ	pb=represent.01	0	root	_
3	a	a	DT	_	8	det	_
4	major	major	JJ	_	8	amod	_
5	global	global	JJ	_	8	amod	_
6	public	public	JJ	_	7	amod	_
7	health	health	NN	_	8	nn	_
8	concern	concern	NN	_	2	dobj	2:A1=PPT
9	.	.	.	_	2	punct	_

1	There	there	EX	_	2	expl	_
2	are	be	VBP	pb=be.02	0	root	_
3	an	an	DT	_	7	det	_
4	estimated	estimate	VBN	p2=JJ|pb=estimate.01	7	amod	_
5	nine	#crd#	CD	_	6	number	_
6	million	#crd#	CD	_	7	num	_
7	people	people	NNS	_	2	attr	8:A0=PAG;19:A0=CAU;2:A1=PPT;4:A1=PPT
8	living	live	VBG	pb=live.01	7	partmod	_
9	with	with	IN	_	8	prep	8:AM-COM
10	HCV	hcv	NNP	_	9	pobj	_
11	in	in	IN	_	10	prep	_
12	Europe	europe	NNP	_	11	pobj	_
13	which	which	WDT	_	19	nsubj	19:R-A0
14	,	,	,	_	19	punct	_
15	if	if	IN	_	16	mark	_
16	untreated	untreated	JJ	p2=VBN	19	advcl	19:AM-ADV
17	,	,	,	_	19	punct	_
18	can	can	MD	_	19	aux	19:AM-MOD
19	cause	cause	VB	pb=cause.01	7	rcmod	_
20	severe	severe	JJ	_	21	amod	_
21	damage	damage	NN	_	19	dobj	19:A1=PPT
22	to	to	IN	_	21	prep	_
23	the	the	DT	_	24	det	_
24	liver	liver	NN	_	22	pobj	_
25	,	,	,	_	24	punct	_
26	including	include	VBG	_	24	prep	_
27	cirrhosis	cirrhosis	NN	p2=NNS	26	pobj	_
28	and	and	CC	_	27	cc	_
29	hepatocellular	hepatocellular	JJ	p2=NN	30	amod	_
30	carcinoma	carcinoma	NN	p2=NNS	27	conj	_
31	(	(	-LRB-	_	30	punct	_
32	HCC	hcc	NNP	_	30	appos	_
33	)	)	-RRB-	_	30	punct	_
34	.	.	.	_	2	punct	_

1	HCV	hcv	NNP	p2=PRP	2	nsubj	2:A0=PAG
2	represents	represent	VBZ	pb=represent.01	0	root	_
3	a	a	DT	_	5	det	_
4	leading	lead	VBG	p2=JJ|pb=lead.01	5	amod	_
5	cause	cause	NN	_	2	dobj	4:A0=PAG;2:A1=PPT
6	of	of	IN	_	5	prep	_
7	liver	liver	NN	_	8	nn	_
8	transplantation	transplantation	NN	_	6	pobj	_
9	in	in	IN	_	8	prep	_
10	Europe	europe	NNP	_	9	pobj	_
11	.	.	.	_	2	punct	_

1	Whilst	whilst	IN	p2=VB	12	mark	_
2	the	the	DT	_	3	det	_
3	number	number	NN	_	12	nsubj	12:A1=PPT
4	of	of	IN	_	3	prep	_
5	patients	patient	NNS	_	4	pobj	_
6	being	be	VBG	_	8	auxpass	_
7	newly	newly	RB	_	8	advmod	8:AM-TMP
8	diagnosed	diagnose	VBN	pb=diagnose.01	15	ccomp	_
9	with	with	IN	_	8	prep	8:A2=PRD
10	HCV	hcv	NNP	_	9	pobj	_
11	is	be	VBZ	_	12	aux	_
12	declining	decline	VBG	pb=decline.01	15	advcl	15:AM-ADV
13	,	,	,	_	15	punct	_
14	it	it	PRP	_	15	nsubj	_
15	takes	take	VBZ	pb=take.10	0	root	_
16	approximately	approximately	RB	_	19	advmod	_
17	20	0	CD	_	19	number	_
18	-	-	SYM	p2=HYPH	19	punct	_
19	30	0	CD	_	20	num	_
20	years	year	NNS	_	15	dobj	15:A1
21	for	for	IN	_	24	mark	_
22	symptoms	symptom	NNS	_	24	nsubj	24:A1=PPT
23	to	to	TO	_	24	aux	_
24	appear	appear	VB	pb=appear.01	15	advcl	15:A0
25	,	,	,	_	24	punct	_
26	with	with	IN	_	24	prep	_
27	HCV	hcv	NNP	p2=CD	28	nn	_
28	cases	case	NNS	_	29	nsubj	29:A0
29	expecting	expect	VBG	pb=expect.01	26	pcomp	_
30	to	to	IN	p2=TO	29	prep	29:A1=PPT
31	peak	peak	NN	_	30	pobj	_
32	between	between	IN	_	31	prep	_
33	2030	0	CD	_	32	pobj	_
34	and	and	CC	_	33	cc	_
35	2035	0	CD	_	33	conj	_
36	.	.	.	_	15	punct	_

1	Dr	dr	NNP	p2=NN	3	nn	_
2	Andrew	andrew	NNP	_	3	nn	_
3	Ustianowski	ustianowski	NNP	_	23	nsubj	23:A0=PAG
4	,	,	,	_	3	punct	_
5	Chair	chair	NNP	p2=NN	3	appos	_
6	of	of	IN	_	5	prep	_
7	the	the	DT	_	11	det	_
8	British	british	JJ	p2=NNP	11	amod	_
9	Viral	viral	NNP	_	11	nn	_
10	Hepatitis	hepatitis	NNP	_	11	nn	_
11	Group	group	NNP	_	6	pobj	_
12	and	and	CC	_	5	cc	_
13	Consultant	consultant	NN	p2=NNP	5	conj	_
14	in	in	IN	_	13	prep	_
15	Infectious	infectious	NNP	p2=JJ	16	nn	_
16	Diseases	diseases	NNP	p2=NNPS	14	pobj	_
17	at	at	IN	_	16	prep	_
18	North	north	NNP	_	19	nn	_
19	Manchester	manchester	NNP	_	21	nn	_
20	General	general	NNP	_	21	nn	_
21	Hospital	hospital	NNP	_	17	pobj	_
22	,	,	,	_	3	punct	_
23	commented	comment	VBD	pb=comment.02	0	root	_
24	:	:	:	_	23	punct	_
25	"	"	``	_	23	punct	_
26	The	the	DT	_	28	det	_
27	treatment	treatment	NN	_	28	nn	_
28	environment	environment	NN	_	34	nsubj	34:A1=PPT
29	in	in	IN	_	28	prep	_
30	hepatitis	hepatitis	NN	p2=NNP	32	nn	_
31	C	c	NN	p2=PRP$	32	nn	_
32	infection	infection	NN	_	29	pobj	_
33	is	be	VBZ	_	34	aux	_
34	evolving	evolve	VBG	pb=evolve.01	23	ccomp	23:A1=PPT
35	rapidly	rapidly	RB	_	34	advmod	34:AM-MNR
36	.	.	.	_	23	punct	_

1	Simeprevir	simeprevir	NNP	p2=NN	2	nsubj	2:A1=PPT;18:A1=PPT
2	is	be	VBZ	pb=be.01	0	root	_
3	a	a	DT	_	9	det	_
4	well	well	RB	_	6	hmod	_
5	-	-	HYPH	_	6	hyph	_
6	tolerated	tolerate	VBN	_	9	amod	_
7	and	and	CC	_	6	cc	_
8	efficacious	efficacious	JJ	_	6	conj	_
9	addition	addition	NN	_	2	attr	2:A2=PRD
10	to	to	IN	_	9	prep	_
11	our	our	PRP$	_	12	poss	_
12	therapies	therapy	NNS	_	10	pobj	_
13	against	against	IN	_	12	prep	_
14	hepatitis	hepatitis	NN	p2=NNP	15	nn	_
15	C	c	NN	p2=NNP	13	pobj	_
16	,	,	,	_	2	punct	_
17	and	and	CC	_	2	cc	_
18	is	be	VBZ	pb=be.01	2	conj	_
19	a	a	DT	_	22	det	_
20	very	very	RB	_	21	advmod	_
21	welcome	welcome	JJ	_	22	amod	_
22	development	development	NN	_	18	attr	18:A2=PRD
23	for	for	IN	_	22	prep	_
24	both	both	CC	p2=PDT	25	preconj	_
25	those	those	DT	_	23	pobj	_
26	with	with	IN	_	25	prep	_
27	genotype	genotype	NN	p2=JJ	26	pobj	_
28	1	0	CD	_	27	num	_
29	and	and	CC	_	25	cc	_
30	those	those	DT	_	25	conj	_
31	with	with	IN	_	30	prep	_
32	genotype	genotype	NN	p2=JJ	31	pobj	_
33	4	0	CD	_	32	num	_
34	.	.	.	_	2	punct	_
35	"	"	''	_	2	punct	_

1	The	the	DT	_	4	det	_
2	EC	ec	NNP	_	4	nn	_
3	marketing	marketing	NN	_	4	nn	_
4	authorisation	authorisation	NN	_	12	nsubjpass	12:A1=PPT
5	for	for	IN	_	4	prep	_
6	simeprevir	simeprevir	NN	p2=FW	5	pobj	_
7	with	with	IN	_	6	prep	_
8	PegIFN	pegifn	NNP	_	10	nn	_
9	+	+	NNP	p2=CC	10	nn	_
10	RBV	rbv	NNP	_	7	pobj	_
11	is	be	VBZ	_	12	auxpass	_
12	based	base	VBN	pb=base.02	0	root	_
13	on	on	IN	_	12	prep	12:A2=DIR
14	a	a	DT	_	17	det	_
15	clinical	clinical	JJ	_	16	amod	_
16	trial	trial	NN	_	17	nn	_
17	programme	programme	NN	_	13	pobj	18:A2=PPT
18	involving	involve	VBG	pb=involve.01	17	partmod	_
19	three	#crd#	CD	_	21	num	_
20	pivotal	pivotal	JJ	_	21	amod	_
21	phase	phase	NN	_	18	dobj	18:A1=PPT
22	3	0	CD	_	23	num	_
23	studies	study	NNS	_	21	appos	_
24	,	,	,	_	21	punct	_
25	with	with	IN	_	21	prep	_
26	over	over	IN	p2=RB	27	quantmod	_
27	1000	0	CD	_	28	num	_
28	patients	patient	NNS	_	25	pobj	_
29	.	.	.	_	12	punct	_

1	The	the	DT	_	2	det	_
2	trials	trial	NNS	_	14	nsubj	14:A0=PAG
3	,	,	,	_	2	punct	_
4	QUEST	quest	NNP	_	6	hmod	_
5	-	-	HYPH	_	6	hyph	_
6	1	0	CD	p2=NNP	2	appos	_
7	,	,	,	_	2	punct	_
8	QUEST	quest	NNP	_	10	hmod	_
9	-	-	HYPH	_	10	hyph	_
10	26	0	CD	p2=NNP	2	appos	_
11	and	and	CC	_	2	cc	_
12	PROMISE	promise	NNP	p2=RB	2	conj	_
13	,	,	,	_	14	punct	_
14	explored	explore	VBD	pb=explore.01	0	root	_
15	the	the	DT	_	16	det	_
16	use	use	NN	_	14	dobj	14:A1
17	of	of	IN	_	16	prep	_
18	simeprevir	simeprevir	NN	p2=NNS	17	pobj	_
19	in	in	IN	_	16	prep	_
20	combination	combination	NN	_	19	pobj	_
21	with	with	IN	_	20	prep	_
22	PegIFN	pegifn	NNP	_	21	pobj	_
23	+	+	CC	p2=SYM	22	cc	_
24	RBV	rbv	NNP	p2=VBN	22	conj	_
25	in	in	IN	_	20	prep	_
26	treatment	treatment	NN	_	28	hmod	_
27	-	-	HYPH	p2=,	28	hyph	_
28	naïve	naïve	NN	p2=JJ	29	nn	_
29	patients	patient	NNS	_	25	pobj	34:A1=PPT
30	and	and	CC	_	29	cc	_
31	patients	patient	NNS	_	29	conj	_
32	who	who	WP	_	34	nsubj	34:R-A1
33	have	have	VBP	_	34	aux	_
34	relapsed	relapse	VBN	pb=relapse.01	29	rcmod	_
35	after	after	IN	p2=RP	34	prep	34:AM-TMP
36	prior	prior	JJ	p2=RB	40	amod	_
37	interferon	interferon	NN	_	39	hmod	_
38	-	-	HYPH	_	39	hyph	_
39	based	base	VBN	_	40	amod	_
40	treatment	treatment	NN	_	35	pobj	_
41	.	.	.	_	14	punct	_

1	All	all	DT	_	3	det	_
2	three	#crd#	CD	_	3	num	_
3	studies	study	NNS	_	4	nsubj	4:A0=PAG;9:A0
4	met	meet	VBD	pb=meet.01	0	root	_
5	their	their	PRP$	_	7	poss	_
6	primary	primary	JJ	p2=NN	7	amod	_
7	endpoints	endpoint	NNS	p2=NN	4	dobj	4:A1=PPT
8	and	and	CC	_	4	cc	_
9	demonstrated	demonstrate	VBD	pb=demonstrate.01	4	conj	_
10	that	that	IN	p2=DT	20	complm	_
11	simeprevir	simeprevir	NN	p2=NNP	20	nsubj	20:A0=PAG
12	,	,	,	_	20	punct	_
13	in	in	IN	_	20	prep	20:AM-ADV
14	combination	combination	NN	_	13	pobj	_
15	with	with	IN	_	14	prep	_
16	PegIFN	pegifn	NNP	_	18	nn	_
17	+	+	NNP	p2=CC	18	nn	_
18	RBV	rbv	NNP	_	15	pobj	_
19	,	,	,	_	20	punct	_
20	achieves	achieve	VBZ	pb=achieve.01	9	ccomp	9:A1=PPT
21	significant	significant	JJ	p2=NN	25	amod	_
22	sustained	sustain	VBD	p2=JJ|pb=sustain.02	25	amod	_
23	virological	virological	JJ	_	25	amod	_
24	response	response	NN	_	25	nn	_
25	rates	rate	NNS	_	20	dobj	20:A1=PPT;22:A1=PPT
26	when	when	WRB	_	27	advmod	27:R-AM-TMP
27	compared	compare	VBN	pb=compare.01	20	advcl	20:AM-TMP
28	with	with	IN	_	27	prep	27:A2=PPT
29	PegIFN	pegifn	NNP	_	28	pobj	_
30	+	+	CC	p2=SYM	29	cc	_
31	RBV	rbv	NNP	p2=RB	29	conj	_
32	alone	alone	RB	p2=JJ	29	advmod	_
33	.	.	.	_	4	punct	_

1	The	the	DT	_	4	det	_
2	EC	ec	NNP	_	3	nn	_
3	marketing	marketing	NN	_	4	nn	_
4	authorisation	authorisation	NN	_	13	nsubj	13:A0
5	for	for	IN	_	4	prep	_
6	the	the	DT	_	7	det	_
7	combination	combination	NN	_	5	pobj	_
8	of	of	IN	_	7	prep	_
9	simeprevir	simeprevir	NN	p2=JJ	8	pobj	_
10	and	and	CC	_	9	cc	_
11	sofosbuvir	sofosbuvir	NN	p2=EX	9	conj	_
12	also	also	RB	_	13	advmod	13:AM-DIS
13	contains	contain	VBZ	pb=contain.01	0	root	_
14	results	result	NNS	_	13	dobj	13:A1
15	from	from	IN	_	14	prep	_
16	the	the	DT	_	19	det	_
17	phase	phase	NN	_	19	nn	_
18	2	0	CD	_	19	num	_
19	study	study	NN	_	15	pobj	_
20	,	,	,	_	19	punct	_
21	COSMOS	cosmos	NNP	p2=NNS	19	appos	_
22	,	,	,	_	19	punct	_
23	in	in	IN	_	19	prep	_
24	treatment	treatment	NN	_	26	hmod	_
25	-	-	HYPH	_	26	hyph	_
26	naïve	naïve	NN	p2=JJ	27	nn	_
27	patients	patient	NNS	_	23	pobj	_
28	.	.	.	_	13	punct	_

1	This	this	DT	_	3	nsubjpass	3:A1=PPT
2	was	be	VBD	_	3	auxpass	_
3	based	base	VBN	pb=base.02	0	root	_
4	upon	upon	IN	_	3	prep	3:A2=DIR
5	prior	prior	RB	p2=JJ	6	advmod	_
6	null	null	JJ	_	12	amod	_
7	responder	responder	NN	_	12	nn	_
8	and	and	CC	_	7	cc	_
9	treatment	treatment	NN	_	11	hmod	_
10	-	-	HYPH	_	11	hyph	_
11	naïve	naïve	NN	p2=JJ	7	conj	_
12	patients	patient	NNS	_	4	pobj	_
13	.	.	.	_	3	punct	_

1	Simeprevir	simeprevir	NNP	p2=NN	3	nsubjpass	3:A1=PPT
2	is	be	VBZ	_	3	auxpass	_
3	taken	take	VBN	pb=take.01	0	root	_
4	once	once	RB	_	6	hmod	_
5	-	-	HYPH	p2=:	6	hyph	_
6	daily	daily	RB	p2=JJ	3	advmod	3:AM-TMP
7	for	for	IN	_	3	prep	3:AM-TMP
8	12	0	CD	_	9	num	_
9	weeks	week	NNS	_	7	pobj	_
10	,	,	,	_	3	punct	_
11	with	with	IN	_	3	prep	_
12	treatment	treatment	NN	_	14	hmod	_
13	-	-	HYPH	_	14	hyph	_
14	naïve	naïve	NN	p2=JJ	19	nn	_
15	and	and	CC	_	14	cc	_
16	prior	prior	RB	p2=JJ	18	hmod	_
17	-	-	HYPH	p2=:	18	hyph	_
18	relapser	relapser	NN	p2=JJR	14	conj	_
19	patients	patient	NNS	_	11	pobj	20:A0=PAG
20	receiving	receive	VBG	pb=receive.01	19	partmod	_
21	pegylated	pegylated	JJ	p2=VBD	22	amod	_
22	interferon	interferon	NN	_	20	dobj	20:A1=PPT
23	and	and	CC	_	22	cc	_
24	ribavirin	ribavirin	NN	p2=VBP	22	conj	_
25	for	for	IN	_	20	prep	20:AM-TMP
26	24	0	CD	_	27	num	_
27	weeks	week	NNS	_	25	pobj	_
28	,	,	,	_	3	punct	_
29	and	and	CC	_	20	cc	_
30	for	for	IN	_	11	conj	_
31	48	0	CD	_	32	num	_
32	weeks	week	NNS	_	30	pobj	_
33	total	total	JJ	_	32	advmod	_
34	by	by	IN	_	3	agent	3:A0
35	those	those	DT	_	34	pobj	36:A1=PPT;38:A1=PPT
36	shown	show	VBN	pb=show.01	35	partmod	_
37	to	to	TO	_	38	aux	_
38	be	be	VB	pb=be.01	36	xcomp	_
39	prior	prior	JJ	p2=RB	41	amod	_
40	non-responder	non-responder	JJ	p2=IN	41	amod	_
41	patients	patient	NNS	_	38	attr	38:A2=PRD
42	(	(	-LRB-	_	41	punct	_
43	including	include	VBG	_	41	prep	_
44	partial	partial	JJ	_	47	amod	_
45	and	and	CC	_	44	cc	_
46	null	null	JJ	_	44	conj	_
47	responders	responder	NNS	p2=NN	43	pobj	_
48	)	)	-RRB-	_	41	punct	_
49	.	.	.	_	3	punct	_

1	It	it	PRP	_	5	nsubjpass	5:A1
2	is	be	VBZ	_	5	auxpass	_
3	generally	generally	RB	_	5	advmod	5:AM-ADV
4	well	well	RB	_	5	advmod	5:AM-MNR
5	tolerated	tolerate	VBN	p2=JJ|pb=tolerate.01	0	root	_
6	,	,	,	_	5	punct	_
7	with	with	IN	_	5	prep	_
8	the	the	DT	_	12	det	_
9	most	most	RBS	_	10	advmod	_
10	common	common	JJ	_	12	amod	_
11	adverse	adverse	JJ	_	12	amod	_
12	events	event	NNS	_	7	pobj	13:A1
13	reported	report	VBN	p2=VBD|pb=report.01	12	partmod	_
14	in	in	IN	_	13	prep	13:AM-LOC
15	clinical	clinical	JJ	_	16	amod	_
16	trials	trial	NNS	_	14	pobj	_
17	(	(	-LRB-	_	16	punct	_
18	incidence	incidence	NN	p2=VB	16	appos	_
19	?	?	.	_	5	punct	_

1	5	0	CD	_	2	num	_
2	%	%	NN	_	0	root	_
3	)	)	-RRB-	_	2	punct	_
4	including	include	VBG	_	2	prep	_
5	nausea	nausea	NN	_	4	pobj	_
6	,	,	,	_	5	punct	_
7	rash	rash	NN	_	5	conj	_
8	,	,	,	_	7	punct	_
9	pruritus	pruritus	NN	p2=NNS	7	conj	_
10	,	,	,	_	9	punct	_
11	dyspnoea	dyspnoea	NN	_	9	conj	_
12	,	,	,	_	11	punct	_
13	blood	blood	NN	_	14	nn	_
14	bilirubin	bilirubin	NN	p2=CD	15	nn	_
15	increase	increase	NN	p2=VB	11	conj	_
16	and	and	CC	_	15	cc	_
17	photosensitivity	photosensitivity	NN	p2=JJ	18	nn	_
18	reaction	reaction	NN	_	15	conj	_
19	.	.	.	_	2	punct	_

1	In	in	IN	_	7	prep	7:AM-LOC
2	March	march	NNP	_	1	pobj	_
3	2013	0	CD	_	2	num	_
4	,	,	,	_	7	punct	_
5	simeprevir	simeprevir	NNP	p2=NN	7	nsubjpass	7:A1=PPT
6	was	be	VBD	_	7	auxpass	_
7	approved	approve	VBN	pb=approve.01	0	root	_
8	for	for	IN	_	7	prep	7:A2=PRD
9	the	the	DT	_	10	det	_
10	treatment	treatment	NN	_	8	pobj	_
11	of	of	IN	_	10	prep	_
12	genotype	genotype	NN	p2=JJ	14	nn	_
13	1	0	CD	_	12	num	_
14	HCV	hcv	NNP	p2=NN	11	pobj	_
15	in	in	IN	_	14	prep	_
16	Japan	japan	NNP	_	15	pobj	_
17	,	,	,	_	7	punct	_
18	in	in	IN	_	7	prep	_
19	Canada	canada	NNP	_	18	pobj	_
20	in	in	IN	_	7	prep	7:AM-TMP
21	September	september	NNP	_	20	pobj	_
22	2013	0	CD	_	21	num	_
23	,	,	,	_	7	punct	_
24	and	and	CC	_	7	cc	_
25	the	the	DT	_	26	det	_
26	US	us	NNP	_	1	pobj	_
27	in	in	IN	_	26	prep	_
28	November	november	NNP	_	27	pobj	_
29	2013	0	CD	_	28	num	_
30	,	,	,	_	26	punct	_
31	with	with	IN	_	5	prep	_
32	the	the	DT	_	35	det	_
33	most	most	RBS	p2=JJS	34	advmod	_
34	recent	recent	JJ	_	35	amod	_
35	approval	approval	NN	_	31	pobj	36:A1=PPT
36	occurring	occur	VBG	pb=occur.01	35	partmod	_
37	in	in	IN	_	36	prep	36:AM-LOC
38	Russia	russia	NNP	_	37	pobj	_
39	in	in	IN	_	36	prep	36:AM-TMP
40	March	march	NNP	_	39	pobj	_
41	2014	0	CD	_	40	num	_
42	.	.	.	_	7	punct	_

1	Following	follow	VBG	_	9	prep	9:AM-TMP
2	the	the	DT	_	5	det	_
3	EC	ec	NNP	_	4	nn	_
4	marketing	marketing	NN	p2=VBG	5	nn	_
5	authorisation	authorisation	NN	_	1	pobj	_
6	,	,	,	_	9	punct	_
7	it	it	PRP	_	9	nsubjpass	_
8	is	be	VBZ	_	9	auxpass	_
9	anticipated	anticipate	VBN	p2=JJ|pb=anticipate.01	0	root	_
10	that	that	IN	p2=DT	13	complm	_
11	simeprevir	simeprevir	NN	p2=NNP	13	nsubj	13:A1=PPT
12	will	will	MD	_	13	aux	13:AM-MOD
13	be	be	VB	pb=be.01	9	ccomp	9:A1=PPT
14	available	available	JJ	_	13	acomp	13:A2=PRD
15	across	across	IN	_	13	prep	13:AM-LOC
16	a	a	DT	_	17	det	_
17	number	number	NN	_	15	pobj	_
18	of	of	IN	_	17	prep	_
19	European	european	NNP	_	20	nn	_
20	Union	union	NNP	_	21	nn	_
21	countries	country	NNS	p2=VBZ	18	pobj	_
22	,	,	,	_	13	punct	_
23	in	in	IN	_	13	prep	13:AM-MNR
24	conjunction	conjunction	NN	_	23	pobj	_
25	with	with	IN	_	24	prep	_
26	reimbursement	reimbursement	NN	_	25	pobj	_
27	,	,	,	_	24	punct	_
28	in	in	IN	_	13	prep	13:AM-TMP
29	the	the	DT	_	31	det	_
30	second	#ord#	JJ	_	31	amod	_
31	half	half	NN	_	28	pobj	_
32	of	of	IN	_	31	prep	_
33	2014	0	CD	_	32	pobj	_
34	.	.	.	_	9	punct	_

1	Simeprevir	simeprevir	NNP	p2=NN	2	nsubj	2:A1=PPT
2	is	be	VBZ	pb=be.01	0	root	_
3	an	an	DT	_	6	det	_
4	NS3/4A	ns3/4a	NNP	_	6	nn	_
5	protease	protease	NN	p2=FW	6	nn	_
6	inhibitor	inhibitor	NN	_	2	attr	8:A1=PRD;2:A2=PRD
7	jointly	jointly	RB	_	8	advmod	8:AM-MNR
8	developed	develop	VBN	pb=develop.02	6	partmod	_
9	by	by	IN	_	8	agent	8:A0=PAG
10	Janssen	janssen	NNP	_	12	nn	_
11	R&D	r&d	NNP	p2=NN	12	nn	_
12	Ireland	ireland	NNP	_	9	pobj	_
13	and	and	CC	_	12	cc	_
14	Medivir	medivir	NNP	_	15	nn	_
15	AB	ab	NNP	_	12	conj	_
16	.	.	.	_	2	punct	_

1	Janssen	janssen	NNP	_	2	nsubj	12:A0=PAG;2:A1=PPT
2	is	be	VBZ	pb=be.01	0	root	_
3	responsible	responsible	JJ	_	2	acomp	2:A2=PRD
4	for	for	IN	_	3	prep	_
5	the	the	DT	_	8	det	_
6	global	global	JJ	_	8	amod	_
7	clinical	clinical	JJ	_	8	amod	_
8	development	development	NN	_	4	pobj	_
9	of	of	IN	_	8	prep	_
10	simeprevir	simeprevir	NN	p2=NNS	9	pobj	_
11	and	and	CC	_	2	cc	_
12	has	have	VBZ	pb=have.03	2	conj	_
13	exclusive	exclusive	JJ	_	17	amod	_
14	,	,	,	_	17	punct	_
15	worldwide	worldwide	JJ	p2=RB	17	amod	_
16	marketing	marketing	NN	_	17	nn	_
17	rights	right	NNS	_	12	dobj	12:A1=PPT
18	,	,	,	_	17	punct	_
19	except	except	IN	_	17	prep	_
20	in	in	IN	_	19	prep	_
21	the	the	DT	_	23	det	_
22	Nordic	nordic	JJ	p2=NNP	23	amod	_
23	countries	country	NNS	_	20	pobj	_
24	.	.	.	_	2	punct	_

1	Medivir	medivir	NNP	p2=NN	2	nn	_
2	AB	ab	NNP	_	3	nsubj	3:A0=PAG
3	retains	retain	VBZ	pb=retain.01	0	root	_
4	marketing	marketing	NN	p2=VBG	5	nn	_
5	rights	right	NNS	_	3	dobj	3:A1=PPT
6	for	for	IN	_	5	prep	_
7	simeprevir	simeprevir	NN	p2=NNS	6	pobj	_
8	in	in	IN	_	7	prep	_
9	these	these	DT	_	10	det	_
10	countries	country	NNS	_	8	pobj	_
11	under	under	IN	_	10	prep	_
12	the	the	DT	_	14	det	_
13	marketing	marketing	NN	_	14	nn	_
14	authorisation	authorisation	NN	_	11	pobj	15:A1=PPT
15	held	hold	VBN	pb=hold.04	14	partmod	_
16	by	by	IN	_	15	agent	15:A0=PAG
17	Janssen	janssen	NNP	_	19	hmod	_
18	-	-	HYPH	_	19	hyph	_
19	Cilag	cilag	NNP	_	21	nn	_
20	International	international	NNP	_	21	nn	_
21	NV	nv	NNP	_	16	pobj	_
22	.	.	.	_	3	punct	_

1	Simeprevir	simeprevir	NNP	p2=NN	3	nsubjpass	3:A1=PPT
2	was	be	VBD	_	3	auxpass	_
3	approved	approve	VBN	pb=approve.01	0	root	_
4	for	for	IN	_	3	prep	3:A2=PRD
5	the	the	DT	_	6	det	_
6	treatment	treatment	NN	_	4	pobj	_
7	of	of	IN	_	6	prep	_
8	genotype	genotype	NN	p2=JJ	7	pobj	_
9	1	0	CD	_	11	num	_
10	hepatitis	hepatitis	NN	_	11	nn	_
11	C	c	NN	p2=NNP	7	pobj	_
12	in	in	IN	_	3	prep	3:AM-TMP
13	September	september	NNP	_	12	pobj	_
14	2013	0	CD	_	13	num	_
15	in	in	IN	_	6	prep	_
16	Japan	japan	NNP	_	15	pobj	_
17	,	,	,	_	9	punct	_
18	in	in	IN	_	8	prep	_
19	November	november	NNP	_	18	pobj	_
20	2013	0	CD	_	19	num	_
21	in	in	IN	_	19	prep	_
22	Canada	canada	NNP	_	21	pobj	_
23	and	and	CC	_	19	cc	_
24	the	the	DT	_	25	det	_
25	US	us	NNP	_	19	conj	_
26	,	,	,	_	21	punct	_
27	and	and	CC	_	18	cc	_
28	in	in	IN	_	18	conj	_
29	March	march	NNP	_	28	pobj	_
30	2014	0	CD	_	29	num	_
31	in	in	IN	_	29	prep	_
32	Russia	russia	NNP	_	31	pobj	_
33	.	.	.	_	3	punct	_

